Collecting global experiences with immunotherapy for metastatic kidney cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The ARON-1 Study is an international multicentric observational study aimed at gathering real-world data on the use of immuno-combinations in patients with metastatic renal cell carcinoma (mRCC). It includes two supplementary studies: ARON-1α, which investigates genomic signatures from tumor samples of patients treated with first-line immuno-combinations, and ARON-1β, which characterizes immune cell populations and their relationship with clinical outcomes. The study focuses on patients who have received specific combinations of immunotherapy treatments. By analyzing this data, the study aims to enhance understanding of treatment efficacy and patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients aged \>18y
* Cytological or Histologically confirmed diagnosis of clear cell or non-clear cell RCC
* Histologically or radiologically confirmed diagnosis of metastatic disease
* First-line treatment with nivolumab plus ipilimumab or nivolumab plus cabozantinib or pembrolizumab plus axitinib or pembrolizumab plus lenvatinib or avelumab plus axitinib or atezolizumab plus bevacizumab

Exclusion Criteria:

* Patients without histologically confirmed diagnosis of RCC
* Patients without histologically or radiologically confirmed metastatic disease
* Patients treated with immuno-combinations not included in the list reported in the Inclusion Criteria Section

Where it's running

• Ospedale di Macerata, UOC Oncologia
  Province of Macerata, Macerata, Italy Recruiting

Study contacts

• Study coordinator: Matteo Santoni, MD, PhD
• Email: mattymo@alice.it
• Phone: +3907332572960

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Lenvatinib and Pembrolizumab With or Without SBRT for Metastatic Kidney Cancer

  This study tests whether adding SBRT to standard lenvatinib plus pembrolizumab helps people with metastatic kidney cancer who have stable disease after initial treatment.

  Recruiting at 8 sites Phase 2 Kidney Cancer Research Bureau · Kazan' and 7 other locations · NCT07928167

• PF-08634404 alone and with other anticancer medicines for adults with advanced kidney cancer.

  This tests whether PF-08634404, given alone or with other cancer medicines, is safe and helps adults with locally advanced or metastatic kidney cancer who have not had prior systemic treatment.

  Recruiting at 157 sites Phase 1/2 Pfizer · Phoenix, Arizona and 182 other locations · NCT07227415

• First-line immune-checkpoint antibody combinations for advanced clear cell kidney cancer

  This trial tests whether combining fianlimab and cemiplimab, with or without ipilimumab, works better than the standard ipilimumab plus nivolumab as first treatment for people with advanced clear cell kidney cancer.

  Recruiting at 5 sites Phase 2 Hoosier Cancer Research Network · Washington D.C., District of Columbia and 4 other locations · NCT07188896

• PET/CT-guided treatment break for metastatic kidney cancer with favorable or intermediate IMDC risk

  This trial tries using PET/CT scans to guide temporary treatment breaks for people with metastatic kidney cancer (IMDC favorable or intermediate risk) who have had at least 12 months of combined PD-1/PD-L1 immunotherapy plus a VEGFR TKI and show a metabolic response.

  Recruiting Phase 2 Jinling Hospital, China · Nanjing, Jiangsu · NCT07175480

• Combining radiotherapy with checkpoint inhibition for metastatic kidney cancer

  This study is testing if combining a new type of radiotherapy with an injectable treatment can help patients with advanced kidney cancer whose disease has continued to progress after previous therapies.

  Recruiting Phase 2 University of Texas Southwestern Medical Center · Dallas, Texas · NCT06601296

• Morning versus afternoon immunotherapy for advanced or metastatic solid tumors

  This trial tests whether giving standard immune checkpoint inhibitor therapy in the morning versus the afternoon changes outcomes for adults with advanced or metastatic solid tumors.

  Recruiting Phase 4 OHSU Knight Cancer Institute · Portland, Oregon · NCT07405086

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.